[Not Available].

S Cosentino; B Cacopardo; B M Celesia; L Ricifari; S Bonaccorsi; G Vinciguerra; A Zagami; M Zuccarello; P Merlo; A Nunnari

Home/Archive/PubMed

PubMed · 14978387

[Not Available].

S Cosentino·B Cacopardo·B M Celesia·L Ricifari·S Bonaccorsi·G Vinciguerra·A Zagami·M Zuccarello·P Merlo·A Nunnari

View original source ↗Export metadata ↓

Abstract

We report a case of oro-pharyngeal and oesophageal ulcerative disease in a AIDS patient. The patient complained of severe oral pain and dysphagia. Systemic manifestations as fever and fatigue were also present. Repeated microbiological exams were negative and therapy with either antibiotics or antiviral agents or corticosteroids or colchicine was unsuccessful. Thus, we started thalidomide: 200 mg/day X 21 days, followed by 100 mg/day X 25 days. A dramatic reduction of symptoms was observed within 15 days from the onset of treatment. The healing of ulcers was evident already one month after the start of therapy. No relevant side effects were reported. Among those patients with AIDS at low risk of side effects, thalidomide may represent a successful therapeutic presidium for severe ulcerative disease of the gastrointestinal tract.

Explore related subjects

English Abstract Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

S Cosentino, B Cacopardo, B M Celesia, L Ricifari, S Bonaccorsi, G Vinciguerra, A Zagami, M Zuccarello, P Merlo, A Nunnari. 1995. [Not Available].. https://pubmed.ncbi.nlm.nih.gov/14978387/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

[Cochrane reviews compared with industry-supported and other meta-analyses of the same drugs--secondary publication].

24 Cochrane reviews were compared with other, closely matched, meta-analyses of the same drugs. The quality score was highest for Cochrane reviews (7 vs. 2, p < 0.01). Of 8 industry-supported reviews, 7 with conclusions all recommended the experimental drug without reservations, compared with none of the Cochrane reviews (p = 0.02) although the estimated treatment effect was similar on average (p = 0.64). Industry-supported reviews were less transparent, had few reservations about methodological limitations of the included trials, and should be read with caution.

English Abstract↗

PubMed2006

[Stimulation with 0,3 mg recombinant human thyrotropin (rhTSH) increases the effect of 131I therapy in patients with nontoxic nodular goiter. A prospective, randomized, double-blind trial--secondary publication].

In a randomized, double-blind, placebo-controlled trial, 57 patients with nontoxic nodular goiter were stimulated with either 0.3 mg recombinant human thyrotropin (rhTSH) or placebo before radioactive iodine 131I therapy. After one year the goiter reduction had improved by 35% compared to conventional 131I therapy. The difference was most pronounced in patients with a large goiter. Adverse effects, including development of permanent hypothyroidism, were significantly more frequent in the rhTSH group. Patient satisfaction was high and uninfluenced by the use of rhTSH.

English Abstract↗

PubMed2006

[Physical activity and clustering of CVD risk factors--secondary publication].

This study aimed to derive guidelines on physical activity. We did a cross-sectional study of 1732 9-year-old and 15-year-old children. Objectively measured physical activity was associated to clustered CVD risk with an OR for the least active of 3.29 compared with the most active quintile. The time spent in moderate activity in children where risk was elevated was less than 116 min per day in 9-year-old and less than 88 min per day in 15-year-old children. Physical activity levels should be higher than the current international guidelines of at least 1 h per day to prevent clustering of CVD risk factors.

English Abstract↗